| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-01-06 | Oncoprex™ and erlotinib | late non-small cell lung cancer (NSCLC) | 2 | Genprex (USA - TX | Cancer - Oncology |
| 2017-01-05 | BioChaperone Lispro® (insuline lispro) and Symlin® (pramlintide), BioChaperone Lispro® (insuline lispro) and Byetta®(exenatide) | type 1 diabetes | 1 | Adocia (France) | Metabolic diseases |
| 2017-01-05 | SGN-CD352A | multiple myeloma | 1 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2017-01-05 | sulopenem | multi-drug resistant infections | 3 | Iterum Therapeutics (Ireland) | Infectious diseases |
| 2017-01-05 | microbiome computational platform | RondinX (Israel) | Inflammatory diseases - Gastrointestinal diseases - Metabolic diseases | ||
| 2017-01-05 | sitravatinib (MGCD516) | advanced solid tumors | 1b | Mirati Therapeutics (USA - CA) | Cancer - Oncology |
| 2017-01-05 | glesatinib (MGCD265) | non-small cell lung cancer (NSCLC) | 2 | Mirati Therapeutics (USA - CA) | Cancer - Oncology |
| 2017-01-05 | arhalofenate | gout | 3 | Cymabay Therapeutics (USA - CA) | Inflammatory diseases |
| 2017-01-05 | ceramide nanoliposome | solid tumors | 1-2 | Keystone Nano (USA - PA) | Cancer - Oncology |
| 2017-01-05 | SL-401 - recombinant human interleukin-3 truncated diphtheria toxin fusion protein | blastic plasmacytoid dendritic cell neoplasm | 1-2 | Stemline Therapeutics (USA - NY) | Cancer - Oncology |
| 2017-01-05 | pacritinib | myelofibrosis | 3 | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) - Baxalta (USA - IL) | Cancer - Oncology |
| 2017-01-04 | navicixizumab - anti-DLL4/VEGF bispecific antibody (OMP-305B83) | metastatic colorectal cancer | 1 | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2017-01-04 | ISIS-GCGR Rx | type 2 diabetes | 2 | Isis Pharmaceuticals (USA) | Metabolic diseases |
| 2017-01-04 | TGR-1202 plus ibrutinib | diffuse large B-cell lymphoma (DLBCL) | 2 | TG Therapeutics (USA - NY) National Cancer Institute (NCI) (USA) | Cancer - Oncology |
| 2017-01-04 | Prostvac® (rilimogene) | asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) | 3 | Bavarian Nordic (Denmark) | Cancer - Oncology |
| 2017-01-03 | IVA337 - lanifibranor - 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid | NASH (non-alcoholic steatohepatitis) | 2 | Inventiva Pharma (France) | Hepatic diseases - Liver diseases |
| 2017-01-03 | IMP761 | Prima Biomed (Australia) | Autoimmune diseases | ||
| 2017-01-03 | coversin (recombinant protein derived from the saliva of the Ornithodoros moubata tick) | paroxysmal nocturnal hemoglobinuria (PNH) | 2 | Akari Therapeutics (USA - NY - UK) | Rare diseases - Immunological diseases |
| 2017-01-03 | ibalizumab | HIV-1 infection | 3 | TaiMed Biologics (Taiwan) Theratechnologies (Canada) | Infectious diseases |
| 2017-01-02 | MM-302 | breast cancer | 2-3 | Merrimack Pharmaceuticals (USA - MA) | Cancer - Oncology |
